image credit: Pixabay

Pfizer to Acquire Biohaven Pharmaceuticals for $11.6 Billion

May 10, 2022

Pfizer and Biohaven Pharmaceuticals have entered into an agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, a dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.

Pfizer will pay approximately $11.6 billion to make the acquisition, which includes Biohaven’s calcitonin gene-related peptide (CGRP) programs including:

Read More on Contract Pharma